Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.